Purpose: To investigate the dose calculation accuracy in water medium of the Advanced Collapsed cone Engine (ACE) for three sizes of COMS eye plaques loaded with low-energy I-125 seeds. Methods: A model of the Oncura 6711 I-125 seed was created for use with ACE in Oncentra â Brachy (OcB) using primary-scatter separated (PSS) point dose kernel and Task Group (TG) 43 datasets. COMS eye plaque models of diameters 12, 16, and 20 mm were introduced into the OcB applicator library based on 3D CAD drawings of the plaques and Silastic inserts. To perform TG-186 level 1 commissioning, treatment plans were created in OcB for a single source in water and for each COMS plaque in water for two scenarios: with only one centrally loaded seed, or with all seed positions loaded. ACE dose calculations were performed in high accuracy mode with a 0.5 9 0.5 9 0.5 mm 3 calculation grid. The resulting dose data were evaluated against Monte Carlo (MC) calculated doses obtained with MCNP6, using both local and global percent differences. Results: ACE doses around the source for the single seed in water agreed with MC doses on average within < 5% inside a 6 9 6 9 6 cm 3 region, and within < 1.5% inside a 2 9 2 9 2 cm 3 region. The PSS data were generated at a higher resolution within 2 cm from the source, resulting in this improved agreement closer to the source due to fewer approximations in the ACE dose calculation. Average differences in both investigated plaque loading patterns in front of the plaques and on the plaque central axes were ≤ 2.5%, though larger differences (up to 12%) were found near the plaque lip. Conclusions: Overall, good agreement was found between ACE and MC dose calculations for a single I-125 seed and in front of the COMS plaques in water. More complex scenarios need to be investigated to determine how well ACE handles heterogeneous patient materials.
INTRODUCTION
The Collaborative Ocular Melanoma Study (COMS) Group provided the first standardized methods for administering ocular brachytherapy treatments for uveal melanoma in 1985, and conducted two randomized trials, the second of which compared enucleation against I-125 plaque radiation therapy for medium-sized choroidal melanomas using the COMS style plaques. 1 Equivalent survival rates were found between the two treatment methods, indicating that ocular brachytherapy is as effective as enucleation, with the added benefit of eye preservation, and for some patients, functional vision retention. 2, 3 The COMS group recognized the uncertainties associated with dosimetry, and therefore used a simplified calculation protocol. The dose was calculated using a pointsource approximation of the brachytherapy seed, and no corrections were made for source anisotropy, the plaque or Silastic insert materials, and photon backscatter or fluorescence photons from the gold-alloy backing.
Though it improves the accuracy of ocular brachytherapy dosimetry, use of the TG-43 formalism with plaque specific correction factors still has a number of limitations. The TG-43 formalism assumes an infinite homogeneous water medium and ignores the effects of interseed attenuation, differing scattering conditions, as well as any nonwater materials present in the treatment field (including applicators and patient tissues). Though the effects of interseed attenuation are very small for ocular brachytherapy (~0.5%), 8 they have been found to be nonnegligible in other brachytherapy treatment sites such as prostate and breast. 11 Differences in scattering conditions due to large air interfaces generally result in an overestimation of the dose when using the TG-43 formalism. The low-density air scatters far fewer photons back into the patient/tissue compared to a fully homogeneous water scenario. For ocular brachytherapy, when accounting for the scattering conditions, the air interface at the patient's face has been found to cause dose decreases of up to 10% near the interface (corneal/aqueous chamber region). 7 These effects were also observed for breast treatments with Ir-192 by Pantelis et al. where the skin dose was overestimated by up to 10% compared to MC simulations. 12 The effects of nonwater applicator materials and patient tissue heterogeneities have been found to significantly impact the dosimetry for several brachytherapy treatment sites; a detailed analysis is given in the AAPM TG-186 report. 11 Within the context of current clinical practice, correction factors account well for the plaque materials, but the impact of patient tissue heterogeneities has only been investigated to a limited extent for ocular brachytherapy. The low-energy photons (20-30 keV) emitted by the radionuclides most commonly used for ocular treatments are highly sensitive to material composition (values of absorbed dose and radiation attenuation), 11, 13 resulting in substantial differences in dose to medium compared to dose to water. Thomson et al. 7 investigated the effects of replacing a water eye model with one made of homogeneous eye material as well as lens material, which caused dose decreases throughout the eye of~2-3% and~7-9% respectively. 7 The tissue heterogeneity effects of a realistic eye model on the dose distributions for ocular brachytherapy have been examined by Lesperance et al., 14 where dose differences of up to 10% within a choroidal melanoma and 14% within the lens of the eye were calculated. Given that ocular brachytherapy does not always achieve local tumour control and that metastases and secondary radiation effects can often occur, more accurate dosimetry is needed.
With the recent advent of commercially available modelbased dose calculation algorithms, the possibility to move away from traditional water-based TG-43 dose calculation in clinical practice now exists. 11 These algorithms allow for consideration of patient scatter conditions that differ from the infinite homogeneous medium assumed in TG-43 single source dosimetry parameter determination, patient tissue heterogeneities as opposed to homogeneous water medium, and nonwater applicator materials (including plastics and metal shields).
With the goal of improving the accuracy of dose calculations and accounting for the COMS plaque effects, the Oncentra â Brachy (OcB) treatment planning system (TPS) with the Advanced Collapsed cone Engine (ACE) (Elekta Brachytherapy, Veenendaal, NL), specifically developed for brachytherapy applications using a collapsed-cone convolution algorithm, was assessed for its potential to be used for ocular brachytherapy dosimetry. The ACE algorithm in OcB has previously only been applied to Ir-192 and Co-60 highdose-rate brachytherapy treatment planning. 15 Therefore, to perform dose calculations with ACE for ocular brachytherapy, a low-energy radiation source as well as eye plaque models first needed to be incorporated into the treatment planning software. Prior to testing ACE in a fully heterogeneous patient scenario, its ability to perform dose calculations for a single low-energy brachytherapy seed and loaded eye plaques in water medium was assessed. In this way, the accuracy with which ACE can account for the high-Z applicator material with a low-energy source is determined separately prior to evaluating its ability to concurrently account for a realistic patient geometry including tissue heterogeneities.
The work presented here outlines the procedure for incorporating an I-125 seed and three sizes of COMS eye plaque models in the software, and reports the subsequent evaluation of the ACE algorithm for dose calculations in a water medium using a research version of OcB (v4.6). This research version incorporates the same dose calculation algorithm as the clinically released version (v4.5), but accepts additional inputs enabling the user to control certain calculation parameters. These include the number of cones/transport directions and the dose calculation grid size, both of which are fixed in the clinical version, the separate calculation/display of each component of dose (primary, first scattered, multiple scattered), and the option to account for source decay. The accuracy of ACE was investigated and current shortcomings in both OcB and ACE were identified. This work presents the first implementation of model-based dose calculations for eye plaques with low energy photon-emitting brachytherapy sources using a commercial software platform to account for heterogeneous plaque materials, potentially allowing for routine clinical dose calculations beyond the TG-43 formalism.
MATERIALS AND METHODS

2.A. Monte Carlo simulations
Brachytherapy dose distributions for comparison with ACE calculated dose distributions were simulated using the MCNP6 (v.1) 16 general purpose Monte Carlo (MC) radiation transport code. The default photon cross-section library, MCPLIB84, was used for all simulations. The I-125 photon spectrum was taken from the National Nuclear Data Centre (NNDC) database, 17 though the 3.77 keV photons were not included as photons with energies below 5 keV do not contribute to dose beyond~0.1 cm in tissue, 9 and only increase the simulation time. Excluding this low-energy photon also more closely matches the NCRP spectrum which was used to create the ACE data (see section 2.B.1.), 18 though no statistically significant differences have been observed when using different energy spectra. 19 All simulations were performed using Mode P (electrons deposit energy locally), as the electron ranges are significantly shorter than the size of the scoring cells.
*F4, *FMESH, and F6 tallies are used to calculate energy deposition within a specified cell per starting particle, with conversion factors (l en /q, from the National Institute of Standards and Technology (NIST) database 20 ) required for the *F4 and *FMESH tallies to convert energy fluence to energy deposited per unit mass. In general, the numbers of particles simulated were chosen such that the statistical uncertainty in dose rate within each scoring cell remained approximately < 0.5% within the regions of interest.
2.A.1. Seed modeling
The I-125 brachytherapy seed created for simulations in MCNP6 was the Oncura OncoSeed model 6711 (GE Healthcare Inc., Arlington Heights, IL, USA). The Nucletron selectSeed model 130.002 (Elekta Brachytherapy, Veenendaal, NL, USA) was initially implemented and evaluated in ACE and based on the results obtained, a number of improvements were made for implementation of the model 6711 seed. 21, 22 The results presented here are primarily for the 6711 seed, though references to the selectSeed will be made for comparison.
The dimensions used for the model 6711 seed were taken from Dolan et al. 23 and Taylor and Rogers 24 (also presented in the CLRP TG-43 parameter database 25 ). The titanium capsule is 4.55 mm long and 0.07 mm thick and has hemispherical end welds which were modeled to be 0.375 mm thick. The inner silver rod has an active length of 2.8 mm and has 45°beveled edges with outer and inner diameters of 0.50 mm and 0.35 mm, respectively, and a density of 10.5 g/ cm 3 . The silver rod has a 1.75 lm thick layer of AgBr:Ag 125 I (2.5:1) with a density of 6.2 g/cm 3 adsorbed onto all surfaces (including the beveled edges). The remaining space is filled with dry air. The dimensions used for the selectSeed model 130.002 I-125 seed for preliminary work were taken from Karaiskos et al. 26 and Taylor and Rogers. 24 I-125 seed implementation involved first creating the seed geometry and benchmarking the corresponding MCNP6 dose distribution against previously published dose data, which was done by calculating TG-43 parameters. To accomplish this, the seed was positioned centrally within a 30 cm radius water sphere with a hydrogen-to-oxygen atomic ratio of 2:1 and a mass density of 0.998 g/cm 3 . The spherical water volume surrounding the seed was divided into a contiguous sampling space bounded by spheres and conics, similar to the geometry described by Rivard et al. 27 The ratios of scored dose (using the F6 tally) were used to calculate the TG-43 parameters: radial dose function (g L r ð Þ) from 0.1 to 10 cm, and anisotropy function (F r; h ð Þ) from 0.1 to 10 cm in 5°i ntervals. Simulations in water were performed with 5 9 10 8 starting particles, resulting in at most 0.5% statistical uncertainties for h > 15°at r = 10 cm (and slightly larger uncertainties~0.1-5% at h ≤ 15°). Statistical uncertainties were 0.06% at 1 cm, and 0.1% at 3 cm on the transverse axis (for a coverage factor of k = 1).
The dose rate constant (Λ) was calculated using an additional simulation to obtain the air-kerma strength, S K . To determine S K , the seed was positioned in vacuum and the energy deposition in air (using a *F4 tally and l en /q values for air from the NIST database 20 with a 5 keV cutoff energy) was scored in a 0.02 lm thick spherical shell at r = 30 cm within a AE7.6°wide conical region to mimic the NIST WAFAC chamber 28 centered on the transverse plane of the seed. 29 The simulation in vacuum was performed with 1 9 10 9 starting particles, resulting in statistical uncertainties of 0.07% for S K and 0.09% for Λ.
2.A.2. COMS plaque modelling
Standard COMS eye plaques with diameters of 12, 16, and 20 mm were modeled in MCNP6 using the standard geometry, seed coordinates, and material properties provided in TG-129. 10 COMS plaques are designed based on a standard eye diameter of 24.6 mm with all seed centers located at a radial distance of 1.4 mm from the outer sclera on the surface of a sphere of radius 13.7 mm. The plaque backings were composed of Modulay, which has a mass composition of 77%, 14%, 8%, and 1%, of gold, silver, copper, and palladium, respectively, and a density of 15.8 g/cm 3 . The Silastic insert was created to fill the space between the Modulay backing and eye sphere, and was made of 39.9%, 28.9%, 24.9%, 6.3%, and 0.005%, of silicone, oxygen, carbon, hydrogen, and platinum by weight, respectively, with a density of 1.12 g/cm 3 . The I-125 sources (described in the previous section) were inserted into the Silastic medium using MCNP6 universe and fill cards, which were copied and translated into the various locations for each COMS plaque size with a cell translation card, based on the seed coordinates from TG-129 and documentation by Kline. 10, 30 The plaque eyelets were not modeled, as they are assumed to have a negligible dosimetric effect due to their small size and the low dose within their vicinity. 7 The eye plaques were centered in a sphere of water with a radius of 20 cm.
Simulations were performed for a single seed in the central slot (SS-COMS) of the plaques (for the 12 and 20 mm plaques; the 16 mm plaque does not have a central slot) and with all seed positions loaded (fully loaded 12, 16, and 20 mm plaques; FL-COMS). The simulations performed with one centrally located seed used 5 9 10 9 starting particles, resulting in statistical uncertainties of at most 0.6% in the eye region in front of the plaque and along the plaque central axis (CAX) up to 30 mm from the Silastic surface. Simulations with fully loaded plaques (8, 13 , and 24 seeds for the 12, 16, and 20 mm plaques, respectively) were performed with 1 9 10 9 starting particles per source. For the fully loaded plaques, only one source was made "active" at a time, but all the other sources were modeled such that interseed effects were included in the FL-COMS simulations. The resulting statistical uncertainties for all FL-COMS simulations were < 0.3% in the eye region in front of the plaque and along the plaque CAXs.
Benchmarking for the COMS plaque simulations was performed in two ways. The first involved running simulations for the heterogeneous and homogeneous material cases (plaque backing and insert materials defined as Modulay and Silastic, respectively, and plaque materials set to water) to calculate the COMS carrier correction factor, TðrÞ, to compare to published values. 7, 10 This was done for the SS-COMS plans. Dose along the CAX of the plaque was scored in 0.5 9 0.5 9 0.5 mm 3 voxels located from 0.5 to 27.5 mm from the outer scleral/Silastic surface. The second benchmarking test was performed for fully loaded plaques by comparing calculated dose rates to data available on the CLRP database. 31 The *FMESH tally was used to create a mesh of the same size and dimensions as that used in the CLRP eye plaque database (array of 0.5 9 0.5 9 0.5 mm 3 voxels extending in a 2.5 9 2.5 9 2.5 cm 3 volume in front of the plaque). Total doses were calculated by summing the dose per starting particle from each simulated source and normalizing by the air-kerma strength per starting particle ( SP S K Þ, yielding values of Gy h À1 U
À1
.
2.B. Implementation and evaluation of ACE
OcB TPS research version 4.6 was used to calculate the dose distribution around the I-125 seed and COMS plaques in water. The ACE algorithm in OcB is based on primaryscatter separated (PSS) dose deposition, in which the total dose is divided into primary, first-scattered, and multiply scattered components. Primary dose is calculated analytically by ray tracing along the path between the source and the point of dose calculation. Each scatter component is parameterized into a point dose deposition kernel which describes the dose distribution around an interaction site. Point dose deposition kernels are initially generated using MC simulations in a homogeneous water medium. The collapsed-cone algorithm improves calculation speed by "collapsing" the transport of energy released onto cone axes (defined by angular discretization) along a radiation transport grid.
For applicators which contain high-Z materials (metals), corrections are made for both intravoxel presence and point dose kernel scaling. For primary dose calculations, each radiation transport step is checked for the presence of tessellation triangles of the applicator, and if present, the step is subdivided and the radiological path length is adjusted for the materials encountered along each substep. For scatter dose calculations, the partial volume of an applicator within a voxel is estimated and used to correct the radiation transport. 32 Additional details about the ACE algorithm and how the CC point dose kernel superposition method is implemented are available in the literature. [32] [33] [34] [35] [36] [37] The implementation of the ACE algorithm is unchanged in the research version compared to its use for high energy HDR source dose calculations in the commercial version of OcB (v4.5), with the exception of the size of the dose calculation grid which in the research version of OcB was set to 0.5 9 0.5 9 0.5 mm 3 instead of 1 9 1 9 1 mm 3 . When using the larger calculation grid size of 1 9 1 9 1 mm 3 , less than 100% effective shielding by the plaque backing was observed. This could be due to the backing material (which is only 0.5 mm thick) being averaged with the adjacent water during the ACE calculation. This observation along with the initial comparisons using the larger calculation grid size (which showed noticeable differences at the edges of the plaque and inner Silastic surface compared to MCNP6 simulated doses), and inaccurate interpolation observed when examining point doses within the larger dose calculation voxels (due to the extremely sharp dose gradients), pointed to the necessity of using a smaller dose calculation grid size for ocular brachytherapy applications. 22 The default number of cones/transport directions for collapsed-cone calculation of first-and multiply scattered dose in the high accuracy mode setting (hACE) in OcB was used for all ACE dose calculations (1620/320 for a single dwell position, and 720/240 for more than one dwell position).
2.B.1. Seed modeling
The selectSeed and model 6711 seeds were both incorporated for use in OcB for ACE calculations. This required TG-43 dosimetry parameters as well as primary-scatter separated (PSS) data, as shown in Fig. 1 for the model 6711 seed. Any photons that leave the Ti source encapsulation are considered primary photons, whereas those that undergo one interaction (without being absorbed) are first-scattered photons and those that undergo any number of subsequent interactions are multiply scattered photons. The PSS data for the selectSeed and model 6711 seed were created by the CLRP group using BrachyDose 24, 38 for the selectSeed, and a recently rewritten version, egs_brachy, 18 for the model 6711 seed (the data for the selectSeed are available in the CLRP online database 25 ). The TG-43 data for the selectSeed were taken from Karaiskos et al. 26 and the PSS data were determined at 1 mm/1°i ncrements from 0.1 to 10 cm and 0°to 90°. The TG-43 data for the model 6711 seed were obtained using egs_brachy and provided by the CLRP group [personal communication, R. Thomson] . The use of the latter dataset (as opposed to using the Dolan et al. 23 dataset) was motivated by inherent issues caused when the TG-43 data are not fully consistent with the PSS MC generated data. These data were re-interpolated onto a regularly spaced grid [1 mm increments for g L r ð Þ, and 2 mm/2°increments for F r; h ð Þ]. The PSS data for the model 6711 seed were determined at higher resolution within the first 2 cm from the source: radially at 0.1 mm increments up to 1 cm from the source, then at 0.5 mm increments for 1 cm < r < 2 cm, and angularly at 1°increments for the primary, first scattered, and multiply scattered dose contributions. The MC generated PSS data are used to create the parameterized point dose deposition kernel data which are then normalized to match the TG-43 calculated dose at 1 cm from the source on the transverse axis, based on the total dose determined using the ACE algorithm in a 15 cm radius spherical water phantom. The separate components of dose as calculated by ACE are also shown in Fig. 1 for comparison with the PSS data.
Both seed models were incorporated into OcB as sources for a Flexitron afterloader (to be compatible with the current catheter-afterloader setup in OcB). The sources were added to the source database in OcB with an initial calibration source strength of 3.81 U. All treatments were planned to start at the source calibration time, and therefore used the initial source strength of 3.81 U.
Initial validations of ACE calculated doses were performed using a single seed in a water box of dimensions 15 9 15 9 15 cm 3 (level 1 commissioning) by comparing the dose distribution around the seed to both TG-43 and MCNP6 simulated doses. The TG-43 and ACE dose data were exported from OcB using a grid size of 0.5 9 0.5 9 0.5 mm 3 centered on the source, and dose was scored around the sources in MCNP6 using a *FMESH tally of the same dimensions and position around the source. The irradiation time was set to deliver 5 Gy at 1 cm from the source along the transverse axis based on TG-43 calculation, and the same total dwell time was used for the ACE calculation. The *FMESH data gives the dose rate in cGy/h/starting particle. The total dose for comparison with OcB is determined by calculating the dose rate per starting particle SP _ D À Á (*FMESH tally value) per source air-kerma strength per starting particle ð SP S K Þ (from single source simulation in vacuum as described in Section 2.A.1), and multiplying by the source air-kerma strength ð source S K Þ and total dwell time (T) required in OcB:
The value for source S K was always 3.81 U. The default dose calculation setting in OcB does not include a correction for source decay, so a constant dose rate is used to calculate the total dose. These simulations used 5 9 10 9 starting particles, resulting in an average statistical uncertainty of 0.5% within the 6 9 6 9 6 cm 3 region used for comparison around the seed, and a maximum statistical uncertainty of 1.3% at the furthest distance from the source examined.
For comparisons between ACE, TG-43, and MCNP6 calculated doses, both for single seed and plaque dosimetry, 3D local (%DD LOCAL ) and global (%DD GLOBAL ) percent differences were used and are defined as:
where r ref for the calculation of %DD GLOBAL is located at 1 cm from the source on the transverse axis. These parameters are used to assess the accuracy of ACE calculated doses as well as the clinical relevancy of dose differences.
2.B.2. COMS plaque modeling
The three COMS plaque models (12, 16 , and 20 mm diameter) were incorporated into the OcB applicator library based on created 3D CAD drawings of each plaque and Silastic insert in SolidWorks 2014 (Dassault Syst emes SolidWorks Corporation, Waltham, MA), again using the dimensions and seed/slot coordinates specified in TG-129 and by Kline. 10, 30 In order to make the applicator models compatible with the afterloader in OcB, virtual catheter lines were created, offset by 0.4 mm along the surfaces of the seed slots in the Silastic insert, in PTC Creo 3.0 CAD software (PTC, Needham, MA, USA). The final assembly of plaque and insert was saved as a CAD STEP file, which was used by Elekta to create an applicator file to add to the Applicator Modeling module (a library containing the geometries of available applicators) in OcB. The latter operation involved creating high resolution tessellations of the assembled plaque and incorporating both the tessellated plaque and catheter line data into a single applicator model. To preserve the correct seed orientation, three dwell positions with a step size of 1 mm are available along each catheter line for each slot in the Silastic insert, though only the first available dwell position (located at the center of each Silastic insert slot) is to be activated. The materials assigned to the COMS plaque backing and seed insert were the same as those used for Modulay and Silastic as described in Section 2.A.2.
Initial dosimetric comparisons were performed by positioning the plaques in the center of a 15 9 15 9 15 cm representative of a 5 mm standard tumor height, assuming 1 mm scleral thickness). Based on TG-43 calculations, the prescribed dose to the reference point was 5 Gy for the SS-COMS plans and 70 Gy for the FL-COMS plans. ACE calculations were performed using the same dwell times as for the TG-43 calculations.
Doses along the plaque CAX were determined at 0.5 mm increments starting at 0.5 mm from the outer scleral surface, and 3D dose grids consisting of 0.5 9 0.5 9 0.5 mm 3 voxels centered at the middle (central source position) of the plaque were exported. The same 3D dose grids were created in MCNP6 using a *FMESH tally for comparative purposes, as were the CAX dose data used to calculate TðrÞ described previously. Doses within a 24.6 mm diameter spherical region in front of the COMS plaques (location of a standard sized eye) extracted from the 3D dose grids were also used to assess the accuracy of ACE within the region of interest (the eye) for ocular brachytherapy treatments.
MCNP6 dose rates per starting particle for each activated source (for FL-COMS plans) were summed together to calculate a total dose rate per starting particle, and total doses for both the SS-COMS and FL-COMS scenarios were determined using Eq. 1 for the same total dwell time as in the ACE calculations and the same value for source S K of 3.81 U.
For the 16 mm FL-COMS plan, additional ACE calculations were performed to investigate if either increasing the number of cones/transport directions or increasing the dose calculation grid resolution would improve the accuracy. First, the ACE calculation was repeated with the number of cones/ transport directions increased to 1620/320 for the first-and multiply scattered doses (default numbers for a single dwell position). Then, the calculation was repeated with the maximum possible resolution given the available computer memory (0.2 9 0.2 9 0.2 mm 3 voxels up to 20 mm from the sources). Dose was exported on the standard 0.5 9 0.5 9 0.5 mm 3 grid for comparison with MCNP6.
RESULTS
3.A. MCNP6 benchmarking
3.A.1. Single seed dosimetry
The majority of TG-43 parameters for the model 6711 seed were within 2% of values obtained from Dolan et al. 23 , respectively (2.5%, 0.6% and 1.4% differences respectively). The average percent difference between MCNP6 simulated values and those given by Dolan et al. for g L r ð Þ and F r; h ð Þ was 1.2% and 0.03% respectively. The average agreement with respect to the CLRP database (using BrachyDose) for g L r ð Þ and F r; h ð Þ was 0.09% and 0.3% respectively.
3.A.2. COMS plaque dosimetry
Values of TðrÞ determined for the SS-COMS plans with one centrally loaded model 6711 seed agreed closely with tabulated data from TG-129, 10 to within~0.5%. For the fully loaded plaques, the average difference in dose rate per air-kerma strength (Gy h À1 U
À1
) in a 2.5 9 2.5 9 2.5 cm 3 volume directly in front of the plaque was at most 0.2%, with a maximum standard deviation of 1.1% for the 12, 16, and 20 mm COMS plaques (excluding regions behind the plaque and where the dose was < 1% of the dose at 6 mm depth), compared to the CLRP Eye Plaque Database data. 31 
3.B. Evaluation of ACE
3.B.1. Single seed dosimetry
For the Nucletron selectSeed, dose differences of > 30% were observed beyond the end welds of the seeds between MCNP6, TG-43, and ACE calculated doses. Average differences in other regions were much smaller, within 1-5%. 21 The minimum radial distance and radial increments for g L r ð Þ and F r; h ð Þ in OcB were 5 mm and the polar angle increments were 5°. Larger differences were observed between MCNP6 simulated TG-43 parameters and those from Karaiskos et al., 26 while the ACE and MCNP6 dose data agreed fairly well, though with an observed offset. As the total PSS point dose kernel data is normalized to match the TG-43 dose at 1 cm on the transverse axis internally within the OcB software, any inherent issues arising from inconsistencies between the TG-43 data and PSS data are expected to propagate to the ACE data.
These results motivated the use of higher resolution TG-43 and PSS data for the model 6711 seed, as well as more up to date TG-43 data determined using similar means as for the PSS data. With such data the accuracy of the ACE algorithm itself, without confounding extraneous differences, could be better examined.
For the model 6711 source, a noticeable improvement in the dose agreement compared to the selectSeed was observed, particularly beyond the end-welds and within close proximity to the source. For the single seed in water, the average difference between ACE and TG-43 within a 6 9 6 9 6 cm Table I . Beyond the 6 9 6 9 6 cm 3 region examined, the differences between ACE and TG-43 decreased, i.e. the 6 9 6 9 6 cm 3 region included the largest relative dose differences. Differences > 10% beyond the end welds were still observed, however, they were confined within a much smaller region than for the selectSeed: within polar angles of approximately AE5°.
Local and global percent differences between ACE and TG-43 up to a maximum radial distance from the center of the seed of 4.3 cm (within a 5 9 5 9 5 cm 3 volume) are shown in Fig. 3 . Larger differences and spread in values in % DD LOCAL at radial distances of 3-4 cm due to the ray artifacts and collapsed-cone approximation, and improved agreement within 2 cm of the source due to the higher resolution PSS data, are seen. The global differences, %DD GLOBAL , normalized to 5 Gy (dose at 1 cm on the transverse axis), show approximately the same differences within the first 1 cm from the source (values within the range [À3%, +1.8%]). Beyond 2 cm, the global percent differences are less than 0.75%. Though the local percent differences are larger in magnitude, they will have less clinical significance for ocular brachytherapy because of the small doses at these distances. In practice, the maximum distance of interest will be approximately 2.5 cm which roughly corresponds to the opposite side of the eye, and at this distance the dose fall-off is substantial.
The agreement between TG-43 and ACE calculated doses compared with MCNP6 doses is summarized in Table I . Agreement between MCNP6 and TG-43 is excellent, with the main differences occurring near the end welds. Though these differences are smaller than what is observed for ACE, there does appear to be a small bias of < 1%. This is also visible in the comparison between ACE and MCNP6 which shows ã 1% larger difference compared to ACE vs. TG-43. Local and global percent differences between ACE and MCNP6 are nearly identical to those between ACE and TG-43, but with ã 1% bias in results. As mentioned previously, since the total PSS point dose deposition kernel data is normalized to match the TG-43 doses at 1 cm on the transverse axis internally within the OcB software, this difference is expected to propagate to the ACE data. Overall, the agreement between ACE and both TG-43 and MCNP6 is within the uncertainties of the TPS calculations (4.7% for k = 1 for TG-43 based planning [based on estimates from TG-138 method 40 ]), and~5% for ACE calculations [41] [42] [43] ). The 5% uncertainty in ACE calculations was determined based on single source TG-186 level 1 commissioning 11 results for the generic high-dose rate Ir-192 source. 42, 43 The differences observed for the model 6711 seed are similar, being in the range [À2%, +4%] for the region of interest for ocular brachytherapy (differences in the Ir-192 source were in the range [À2%, +3%]). The former differences are found within a 3D volume around the source as compared with the 2D planes used by Ballester et al., 43 and therefore involve a much larger number of voxels. Given the similar level of agreement for the model 6711 source as compared with the generic Ir-192 source, the same level of uncertainty for ACE calculations of 5% will be adopted.
3.B.2. COMS plaque dosimetry
Percent differences along the plaque CAX for the SS-and FL-COMS plans for the model 6711 seed are shown in Fig. 4 . The maximum differences at the outer scleral surface for the model 6711 seed were up to 5 times smaller than for the selectSeed. 21, 22 This is attributed to the lower resolution of the PSS data for the selectSeed compared to the model 6711 seed, as well as to the use of older TG-43 data which showed poorer agreement with both MCNP6 and ACE. Differences decreased up to~10 mm, then increased slightly when moving further away from the sources/plaque (beyond 20 mm) as the collapsed-cone approximation becomes less accurate. This trend is also observed for the single seed data in water along the source transverse axis. However, differences are consistently lower for the model 6711 seed compared to the selectSeed for the entire distance range examined along the plaque CAX. ACE calculated doses for the 16 mm COMS plaque showed better agreement with MCNP6 doses compared to the other plaque sizes, even at shallow depths. A likely cause of this is the lack of a central source position in this plaque, such that any position on the CAX is at a greater average distance to the sources compared to the other two plaques which have a central source. For this plaque, the differences between ACE and MCNP6 doses are within AE1.5% from 0.5 to 27.5 mm from the outer scleral surface, with an average difference of 0.3%.
The percent differences between ACE and MCNP6 for all plaque plans (SS-and FL-COMS) and for all three plaque sizes within the spherical eye region in front of the plaque showed overall good agreement; values are summarized in Table II . The local percent dose difference in the central plane of the 16 mm COMS plaque fully loaded with 6711 seeds is shown in Fig. 5(a) . For the most part the agreement between ACE and MCNP6 within the standard spherical eye region is within the uncertainty of ACE dose calculation (5%); however, larger differences are observed in the penumbral shadow of the plaque where dose differences vary from [À12%, +8%]. These latter differences are likely due to the intra-voxel presence of the plaque within the background water material, which for primary dose is handled quite carefully but for scattered dose involves larger approximations. 37 Other contributing factors are the simplifications made in radiation source modeling and angular discretization of photon transport in ACE. The PSS data used by ACE is determined for a line source, however, radiation sources in ACE are implemented as point sources, with corrections to account for this. 37 The combined effect is seen as single high and low percentage difference streaks near the plaque lip for the SS-COMS plans, and multiple streaks (due to multiple seeds) for the FL-COMS plans. Large percent differences are observed behind the plaque, however, the doses are extremely low and these differences are not of clinical concern.
Increasing the number of cones/transport directions as well as decreasing the calculation voxel size resulted in negligible changes in the ACE doses, with the exception of an improvement in dose agreement immediately surrounding the entire plaque (behind the Modulay plaque backing and in front of the Silastic insert). At these locations there is less voxel averaging between plaque and water material, but this improvement was only seen within~0.5-1.0 mm from the plaque. Ray artifacts were more evident with the smaller dose calculation grid. The default number of cones with multiple dwell positions (720/240) is therefore sufficient, and negligible gains are achieved by increasing the dose calculation resolution. Also, both of these changes result in a~2-3 times increase in dose calculation time.
From the examination of plaque dosimetry in water, expected differences when moving forward to more complex scenarios will be at the penumbral edges of the plaque. Depending on the position of the plaque relative to the optic nerve, optic disc, and fovea, these sensitive structures could be located in the plaque penumbra, and therefore the accuracy of ACE in these regions would be of concern and will warrant careful examination. Doses within a tumour (the region adjacent to the plaque), and along the plaque CAX are expected to agree fairly well.
Global percent dose differences in the fully loaded 16 mm COMS plaque relative to the dose at 5 mm from the inner sclera (reference tumour apex location) are shown in the central plane of the plaque in Fig. 5(b) . The differences within the penumbra are within AE1.5% and the largest difference immediately adjacent to the plaque is~5%. This comparison is useful to determine whether the observed differences might have a clinical impact.
DISCUSSION
For the single source dosimetry, a clear improvement in the accuracy of the ACE calculation was obtained by using higher resolution PSS data and more current/accurate TG-43 data that better matches the PSS data. A further improvement could potentially be realized if the PSS data were determined at the higher resolution of 0.1 mm/1°intervals for a region up to 2 cm from the source (or up to 2.5 cm for ocular brachytherapy applications, although given the small values of global percent differences at 2 cm and beyond, any clinical advantage would be minimal considering how quickly the dose falls off with increasing distance from the source).
For the plaques in water, ACE accounted for the heterogeneous plaque materials quite well, with the advantage that no correction factors, such as those implemented in the Plaque Simulator TPS, are needed. 44 Currently in Plaque Simulator, the same COMS plaque carrier correction factor is used for all I-125 source models, whereas it has been shown that different models will have slightly different dose reductions in front of the plaque. 8 By providing source specific PSS data in OcB for the ACE calculation, differences caused by the length of the inner active rod, distribution of activity, construction of the source etc., are inherently accounted for. Although these differences are generally quite small, particularly when compared to other systematic uncertainties present in the dose calculations and dose delivery, they do represent an advantage when using ACE.
The doses along the plaque CAX and within the central part of the eye agreed well within the uncertainties of ACE calculations. However, a distinct limitation of ACE was found at the plaque penumbra. Depending on the plaque position, critical structures could be located in this region, and therefore the accuracy of the dose calculated within these structures could be limited. That being said, depending on the distance of a critical structure from the plaque, these doses could be quite low. Therefore, a~10% uncertainty in dose might not be important clinically, particularly if the maximum dose is well below the threshold tolerance dose for the critical structure in question.
The larger differences in the plaque penumbra for the COMS plaques are limited to a conical shell volume around the eye, and it is expected that similarly constructed plaques would show a similar effect (e.g. ROPES plaques [stainless steel backing with acrylic insert], 45 COMS type plaques with thin acrylic inserts or no inserts [46] [47] [48] . However, if a slotted style of plaque (e.g. Eye Physics plaques 49 ) was incorporated into OcB, each seed would be located adjacent to smaller interior slot edges, and the associated penumbral differences could potentially be larger and affect a larger volume of the eye region. Different styles of plaques would need to be evaluated individually to determine how well ACE could handle the dose modifying effects of the applicator.
CONCLUSION
To explore the possibility of performing patient specific model-based dose calculations for ocular brachytherapy, two I-125 source models and three sizes of COMS plaques were added to a research version of the Oncentra Brachy TPS incorporating the ACE algorithm. MC simulations using MCNP6 were performed to supply reference dosimetry data for comparison. Overall, ACE dosimetry showed good agreement with MC for single sources in water within 2 cm of the source, and within a standard eye model volume and along the plaque CAX for both a single seed in the central slot and fully loaded COMS plaques, on average within ≤ 2.5%. However, doses in the plaque penumbra showed larger differences of up to 12%, within which critical structures in the eye (optic disc, macula) could be located. More complex scenarios with heterogeneous patient tissues will be used to further explore this discrepancy.
